Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Apr 20;39(12):1371-1382. doi: 10.1200/JCO.20.02759. Epub 2021 Feb 22. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

2021 EvidenceUpdates

2. Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen

Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen - Repository of AIHTA GmbH English | Browse - - - Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC (...) ) previously treated with a docetaxel containing regimen Grössmann, N. (2020): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Oncology Fact Sheet Nr. 8. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 65kB Item Type: Oncology Fact Sheets Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 8 Deposited on: 02 Jun 2020 16:06 Last

2021 Austrian Institute of Health Technology Assessment

3. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial Full Text available with Trip Pro

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial JAMA Netw Open Actions . 2021 Jan 4;4(1):e2034633. doi: 10.1001/jamanetworkopen.2020.34633. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized

2021 EvidenceUpdates

4. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer

Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer CUAJ – CUA Best Practice Report Shayegan et al BPR: PSMA PET in prostate cancer 1 © 2021 Canadian Urological Association Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic (...) resonance (MR) in prostate cancer Bobby Shayegan *1 ; Katherine Zukotynski *2 ; François Bénard 3,4 ; Cynthia Ménard 5 ; Golmehr Sistani 6 ; Glenn Bauman 7 ; Patrick Veit-Haibach 8 ; Ur Metser 9 1 Department of Urology, McMaster University, Hamilton, ON, Canada; 2 Departments of Medicine and Radiology, McMaster University, Hamilton, ON, Canada; 3 PET Functional Imaging, BC Cancer, Vancouver, BC, Canada; 4 Department of Radiology, University of British Columbia, Vancouver, BC, Canada; 5 Department

2021 Canadian Urological Association

5. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer Guideline 27-2 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer M.A. Haider, J. Brown, J. Chin, A. Loblaw, N. Perlis, N. Schieda, and the MPMRI in the Diagnosis of Clinically Significant Prostate Cancer Guideline Development Group (...) (Vancouver Style): Haider MA, Brown J, Chin J, Loblaw A, Perlis N, Schieda N. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer. Toronto (ON): Ontario Health (Cancer Care Ontario); 2021 February 11. Program in Evidence-Based Care Guideline No.: 27-2 Version 2, available on the OH (CCO) website. Copyright This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express

2021 Cancer Care Ontario

6. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Jan 26;JCO2003256. doi: 10.1200/JCO.20.03256. Online ahead of print. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Emory University, Atlanta, GA. 2 American Society of Clinical Oncology, Alexandria, VA. 3 Erasmus MC

2021 EvidenceUpdates

7. Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC)

Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC) Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) - Repository of AIHTA GmbH English | Browse - - - Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) Grössmann, N. (2020): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Oncology Fact Sheet Nr. 23. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z

2021 Austrian Institute of Health Technology Assessment

8. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) Full Text available with Trip Pro

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom. 2 University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. 3 Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, United Kingdom. 4 Lancashire Teaching Hospitals NHS

2021 EvidenceUpdates

9. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) CUAJ • February 2021 • Volume 15, Issue 2 © 2021 Canadian Urological Association CUA-CUOG GUIDELINE E81 Cite as: Saad F , Aprikian A, Finelli A, et al. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2021;15(2):E81-9. http://dx.doi.org (...) modified Oxford Center for Evidence-Based Medicine grading system. Based on a modified GRADE methodology, the strength of each recommendation is represented by the words STRONG or WEAK. Introduction Castration-resistant prostate cancer (CRPC) is defined by dis - ease progression despite castrate levels of testosterone and may present as either a continuous rise in serum prostate- specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases. Advanced

2021 Canadian Urological Association

10. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) . A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Radiation Oncology, University of California, Los Angeles, CA, USA. 2 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. 3 Department of Medicine, Statistics Core, University of California, Los Angeles, CA, USA. 4 Department of Urology, Mayo Clinic, Rochester, MN, USA

2021 EvidenceUpdates

11. Relugolix (Orgovyx) - To treat advanced prostate cancer

Relugolix (Orgovyx) - To treat advanced prostate cancer Drug Approval Package: ORGOVYX U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ORGOVYX Company: Myovant Sciences GmbH Application Number: 214621 Approval Date: 12/18/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package

12. Gallium 68 PSMA-11 - For detection and localization of prostate cancer

Gallium 68 PSMA-11 - For detection and localization of prostate cancer Drug Approval Package: GALLIUM GA 68 PSMA-11 U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GALLIUM GA 68 PSMA-11 Company: University of California Los Angeles Application Number: 212642 Approval Date: 12/01/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2021 FDA - Drug Approval Package

13. Apalutamide (Erleada) - for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Apalutamide (Erleada) - for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) Published 18 January 2021 Statement of advice SMC2323 apalutamide 60mg film-coated tablets (Erleada®) Janssen-Cilag Ltd 4 December 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation apalutamide (Erleada®) is not recommended for use within NHSScotland. Indication under review: in adult men for the treatment of metastatic hormone-sensitive prostate cancer

2021 Scottish Medicines Consortium

14. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) : 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Urology, University Hospital, St. Etienne, France. Electronic address: nicolas.mottet@chu-st-etienne.fr. 2 Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands. 3 Hasselt, Belgium. 4 Department

2021 EvidenceUpdates

15. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) 2;3(11):e2025826. doi: 10.1001/jamanetworkopen.2020.25826. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis , , , , , Affiliations Expand Affiliations 1 Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington. 2 Markey Cancer Center, University of Kentucky, Lexington. 3 University of Kentucky College of Pharmacy, Lexington. PMID: 33201234 PMCID: DOI: Free PMC

2021 EvidenceUpdates

16. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer T echnology appraisal guidance Published: 25 November 2020 www.nice.org.uk/guidance/ta660 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

17. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial Lancet Oncol Actions . 2020 Oct;21(10):1341-1352. doi: 10.1016/S1470-2045(20)30454-X. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Institut Bergonié, Bordeaux, France

2020 EvidenceUpdates

18. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study - PubMed This site needs JavaScript to work properly. Please enable it to take (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial Lancet Oncol Actions . 2020 Nov;21(11):1513-1525. doi: 10.1016/S1470-2045(20)30449-6. Epub 2020 Sep 11. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department

2020 EvidenceUpdates

19. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Apalutamid (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 29 June 2020). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Extract IQWiG Reports – Commission No. A20-36 Apalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A20-36 Version 1.0 Apalutamide (prostate cancer) 29 June 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Apalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Apalutamide (prostate cancer) - Addendum to Commission A20-20

Apalutamide (prostate cancer) - Addendum to Commission A20-20 1 Translation of addendum A20-62 Apalutamid (Prostatakarzinom) – Addendum zum Auftrag A20-20 (Version 1.0; Status: 6 August 2020). Please note: Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 6 August 2020 1.0 Commission: A20-62 Version: Status: IQWiG (...) Reports – Commission No. A20-62 Apalutamide (prostate cancer) – Addendum to Commission A20-20 1 Addendum A20-62 Version 1.0 Apalutamide – Addendum to Commission A20-20 6 August 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Apalutamide (prostate cancer) – Addendum to Commission A20-20 Commissioning agency Federal Joint Committee Commission awarded on 28 July 2020 Internal Commission No. A20

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)